Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) insider James E. Flynn sold 547,886 shares of the firm’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $15.66, for a total value of $8,579,894.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at 15.20 on Tuesday. The stock’s market cap is $657.92 million. Vanda Pharmaceuticals Inc. has a 12 month low of $6.91 and a 12 month high of $16.50. The company’s 50-day moving average price is $13.91 and its 200-day moving average price is $10.73.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.12. The firm earned $36.02 million during the quarter, compared to the consensus estimate of $36.03 million. Vanda Pharmaceuticals had a negative return on equity of 22.51% and a negative net margin of 31.85%. The firm’s revenue was up 30.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.13) EPS. Equities analysts forecast that Vanda Pharmaceuticals Inc. will post ($0.61) earnings per share for the current year.

VNDA has been the topic of several research analyst reports. JMP Securities raised their price objective on Vanda Pharmaceuticals from $18.00 to $22.00 and gave the company a “market outperform” rating in a report on Friday, August 26th. Brean Capital reissued a “buy” rating and issued a $24.00 price objective (up from $20.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 29th. Jefferies Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Friday, June 10th. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $16.00 price target on shares of Vanda Pharmaceuticals in a research note on Thursday, July 28th. Finally, Zacks Investment Research lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 6th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $18.17.

A number of hedge funds have recently bought and sold shares of VNDA. Acrospire Investment Management LLC bought a new stake in Vanda Pharmaceuticals during the first quarter valued at approximately $102,000. BlackRock Group LTD increased its position in shares of Vanda Pharmaceuticals by 62.7% in the first quarter. BlackRock Group LTD now owns 14,599 shares of the biopharmaceutical company’s stock worth $123,000 after buying an additional 5,625 shares during the period. Bank of Montreal Can acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth about $132,000. UBS Asset Management Americas Inc. increased its position in shares of Vanda Pharmaceuticals by 10.9% in the second quarter. UBS Asset Management Americas Inc. now owns 16,300 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 1,600 shares during the period. Finally, Paloma Partners Management Co acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth about $192,000. 86.06% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

5 Day Chart for NASDAQ:VNDA

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.